One of the nation's largest makers of machines for sleep apnea sufferers has agreed to pay $479 million to compensate customers who bought the devices and suffered injuries due to foam spewing into ...
CPAP sleep apnea machine maker Philips Respironics agreed to pay at least $479 million in a settlement over alleged health risks from toxic sound reducing foam, lawyers for the plaintiff announced ...
(Reuters) - Dutch medical equipment company Philips has been hit with a $200 million lawsuit accusing it of deceiving the public and the healthcare industry by falsely linking the problems with its ...
The ongoing recall of millions of breathing devices made by Philips has been botched and belabored at nearly every turn: It took more than a decade after users first reported the soundproofing foam in ...
Plaintiffs cannot seek damages because they have no injury, company says CPAP machines and mechanical ventilators recalled over issues with foam (Reuters) - Dutch conglomerate Koninklijke Philips NV ...
WASHINGTON — A massive recall of millions of sleep apnea machines has stoked anger and frustration among patients, and U.S. officials are weighing unprecedented legal action to speed a replacement ...
Medical device maker Philips announced a nearly $1.1 billion personal injury settlement over some of its CPAP, ventilators and BiPAP machines that were at the heart of a massive recall in 2021. The ...
Millions of Americans’ bedtime routine includes wearing a mask attached to a respiratory machine that pushes air into their lungs, supporting their breathing during sleep. These airway pressure ...
The US Food and Drug Administration issued a Class I recall Friday, the most serious type of recall, for certain Philips Respironics DreamStation1 CPAP machines. A Class I recall means the FDA has ...
Philips released the latest set of safety test results on Tuesday, covering all CPAP and BiPAP sleep therapy machines included in the recall—which together make up about 95% of all of the recalled ...
ResMed (RMD) shares fell in the premarket on Wednesday after Morgan Stanley downgraded the respiratory device maker, citing headwinds from the GLP-1 class of weight-loss drugs and a potential re-entry ...